Ultralife Corp insider Form 4 shows CEO stock purchase
Rhea-AI Filing Summary
Ultralife Corporation (ULBI) reported an insider share purchase by its President and CEO, who is also a director. On 11/19/2025, the executive bought a total of 2,000 shares of common stock in two open-market transactions. The purchases were made at prices of $4.943 and $4.99 per share, increasing the executive’s direct beneficial ownership to 24,874 shares after the transactions. This filing reflects the executive’s personal investment activity in Ultralife stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock; $.10 par value | 1,000 | $4.943 | $5K |
| Purchase | Common Stock; $.10 par value | 1,000 | $4.99 | $5K |
Footnotes (1)
FAQ
What insider transaction did Ultralife (ULBI) report in this Form 4?
The filing reports that the President and CEO, who is also a director, bought 2,000 shares of Ultralife common stock on 11/19/2025 in open-market purchases.
What is the reporting person’s role at Ultralife (ULBI)?
The reporting person serves as both a Director and an Officer, holding the title of President and CEO of Ultralife Corporation.
Were any derivative securities reported for Ultralife (ULBI) in this Form 4?
The section for derivative securities was included in the form, but no specific derivative transactions or holdings were reported in the provided table.
Is this Ultralife (ULBI) Form 4 filed by one or multiple reporting persons?
The form is indicated as being filed by one reporting person, reflecting the transactions of a single executive.